Home Newsfeeds Deutsche Bank Downgrades Wendy’s to Hold, Announces $23 Price Target

Deutsche Bank Downgrades Wendy’s to Hold, Announces $23 Price Target

Deutsche Bank analyst Brian Mullan downgrades Wendy's (NASDAQ:WEN) from Buy to Hold and announces $23 price target.

byBenzinga Newsdesk

January 17, 2023

1 minute read

Deutsche Bank analyst Brian Mullan downgrades Wendy’s (NASDAQ:WEN) from Buy to Hold and announces $23 price target.

Whistleblower Lawsuit Alleges Bribery Scheme: Medtronic Denies Allegations of Kickback Scheme, Endangering Patients’ Lives

By Vandana Singh

July 13, 9:20 AM

Sales representatives from Medtronic plc (NYSE: MDT) allegedly operated a bribery scheme at a Kansas veterans hospital.

MDT

Analyst Ratings

Where Kimco Realty Stands With Analysts

By Benzinga Insights

August 16, 2:11 PM

Within the last quarter, Kimco Realty (NYSE:KIM) has observed the following analyst ratings:

KIM

B. Riley Securities Maintains Buy on Novavax, Lowers Price Target to $83

By Benzinga Newsdesk

October 14, 8:08 AM

B. Riley Securities analyst Mayank Mamtani maintains Novavax (NASDAQ:NVAX) with a Buy and lowers the price target from $126 to $83.

NVAX

Nanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial

By Vandana Singh

September 22, 7:22 AM

Nanobiotix (NASDAQ: NBTX) determined the recommended phase 2 dose (RP2D) of the NBTXR3 combo regime for inoperable locoregional recurrent or recurrent and metastatic head and neck squamous cell carcinoma that is resistant to prior immunotherapy.

BMY

Deutsche Bank Downgrades Wendy’s to Hold, Announces $23 Price Target

Related Posts

Whistleblower Lawsuit Alleges Bribery Scheme: Medtronic Denies Allegations of Kickback Scheme, Endangering Patients’ Lives

Where Kimco Realty Stands With Analysts

B. Riley Securities Maintains Buy on Novavax, Lowers Price Target to $83

Nanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial